GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » EV-to-EBIT

Fresenius Medical Care AG (Fresenius Medical Care AG) EV-to-EBIT

: 14.83 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fresenius Medical Care AG's Enterprise Value is $23,330 Mil. Fresenius Medical Care AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,573 Mil. Therefore, Fresenius Medical Care AG's EV-to-EBIT for today is 14.83.

The historical rank and industry rank for Fresenius Medical Care AG's EV-to-EBIT or its related term are showing as below:

FMS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.71   Med: 13.89   Max: 18.08
Current: 14.84

During the past 13 years, the highest EV-to-EBIT of Fresenius Medical Care AG was 18.08. The lowest was 7.71. And the median was 13.89.

FMS's EV-to-EBIT is ranked better than
62.21% of 426 companies
in the Healthcare Providers & Services industry
Industry Median: 18.645 vs FMS: 14.84

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Fresenius Medical Care AG's Enterprise Value for the quarter that ended in Dec. 2023 was $25,001 Mil. Fresenius Medical Care AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,573 Mil. Fresenius Medical Care AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 6.29%.


Fresenius Medical Care AG EV-to-EBIT Historical Data

The historical data trend for Fresenius Medical Care AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.41 13.73 15.44 14.05 15.68

Fresenius Medical Care AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.05 16.71 17.09 18.00 15.68

Competitive Comparison

For the Medical Care Facilities subindustry, Fresenius Medical Care AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius Medical Care AG EV-to-EBIT Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fresenius Medical Care AG's EV-to-EBIT falls into.



Fresenius Medical Care AG EV-to-EBIT Calculation

Fresenius Medical Care AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=23329.823/1573.34
=14.83

Fresenius Medical Care AG's current Enterprise Value is $23,330 Mil.
Fresenius Medical Care AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,573 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresenius Medical Care AG  (NYSE:FMS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fresenius Medical Care AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1573.34/25001.04141
=6.29 %

Fresenius Medical Care AG's Enterprise Value for the quarter that ended in Dec. 2023 was $25,001 Mil.
Fresenius Medical Care AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,573 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresenius Medical Care AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
Executives
Helen Pring Giza Board of Directors